Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
P&G struggles with developed market hump; divested Pfizer Nutrition grows 18% in Q2; Teva heralds PGT Healthcare’s Vicks launch in Poland and Russia; Ganeden, Airborne deals lift Schiff Nutrition’s fiscal 2012; more Sales & Earnings In Brief.
You may also be interested in...
Activist Investor May Push P&G To Sell Non-Core Brands, Oust CEO McDonald
Changes may be ahead for Procter & Gamble following William Ackman and Pershing Square Capital Management’s investment in the consumer products giant. Analysts suggest the activist investor may push to replace CEO Bob McDonald and divest non-core brands.
In Brief
Novartis begins OTC recovery with Excedrin; Abbott Nutrition up double digits in Q2; trade groups discuss supplement GMPs with Sen. Durbin; ChromaDex licenses patents for nicotinamide riboside; Nature Made supplements alleged to contain pork by-products; more news In Brief.
Herbalife Shakes Off Market Dive After Investor Scare
David Einhorn’s questions during Herbalife’s Q1 earnings call sowed market doubt about the firm, whose stock dropped about 20% May 1. But analysts called the panic behind the sell-off “unwarranted” given the firm’s strong Q1 performance and sound fundamentals.